Latest news with #MASLD
Yahoo
13 hours ago
- Business
- Yahoo
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population. Despite the scale of these problems, treatment options remain limited. The Company believes that its novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This patent filing is part of Clearmind's ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company developing therapies for central nervous system disorders. 'Our goal is to bring meaningful innovation to areas with high unmet medical need,' said Dr. Adi Zuloff-Shani, CEO of Clearmind. 'This patent filing reflects our commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease.' About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relationsinvest@ Telephone: (604) 260-1566US: CMND@ General InquiriesInfo@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its novel approach of the combination therapy of MEAI and PEA has the potential to offer a safe and effective therapeutic alternative, its goal to to bring meaningful innovation to areas with high unmet medical need and its commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
Yahoo
13 hours ago
- Business
- Yahoo
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) ('Clearmind') has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population, according to the article titled 'Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons,' published in August 2023. Despite the scale of these problems, treatment options remain limited. According to Clearmind, the novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Marketplace. About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind's intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, that this proprietary combination is designed to address two significant global health challenges: obesity and MASLD, and that it has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. Since such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@ +972-3-6167055Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Tribune
20 hours ago
- Health
- Daily Tribune
Liver cancer to double worldwide, most of it preventable: study
AFP | Paris The number of people with liver cancer will nearly double worldwide by 2050 unless more is done to address preventable causes such as obesity, alcohol consumption and hepatitis, a study warned Tuesday. New cases of liver cancer -- the sixth most common form of the disease -- will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal. It is also the third deadliest of all cancers, with the study predicting it would take 1.37 million lives by the middle of the century. However three out of five cases of liver cancer could be prevented, the international team of experts said. The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called MASLD, which was previously known as non-alcoholic fatty liver disease. The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022.
Boston Globe
a day ago
- Health
- Boston Globe
Three out of five liver cancer cases are preventable, study finds
Advertisement The findings align with what liver specialists have seen in their clinics for years. 'Liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable,' said Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study. Improved screening, vaccination and treatment in recent years have helped stem viral hepatitis, especially in the United States. But the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, 'has been underrecognized and underestimated,' said Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, who was not associated with the study. Advertisement A 'highway' to liver cancer A vast majority of liver cancers arise in people with cirrhosis, said Dr. Hashem El-Serag, the chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study. Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally. The hepatitis B and C viruses cause inflammation that, if left untreated, can scar and damage the liver, potentially leading to cirrhosis. And both alcohol and metabolic dysfunction lead to abnormal deposits of fat in the liver, which can also result in inflammation. Related : Lee said the accumulation of fat and inflammation acted as a 'highway' to liver scarring, which in turn can injure DNA and lead to cancer. 'There could be multiple ramps to get onto that highway,' he said. Why disease may go undetected The new paper found that the share of liver cancers resulting from hepatitis B and hepatitis C is expected to drop to 63% in 2050, from 68% in 2022. But the burden of liver cancers resulting from alcohol and MASLD is expected to grow. An estimated 4 in 10 adults worldwide have MASLD, a condition in which fat builds up in the liver. Risk factors include obesity and Type 2 diabetes. A subset of patients with MASLD will go on to develop an advanced form called metabolic dysfunction-associated steatohepatitis, or MASH, which has been described as a silent killer because it can progress to cirrhosis and liver cancer without being noticed. Current guidance recommends monitoring for liver cancers in patients who have a history of viral hepatitis or established cirrhosis. Patients with MASH typically don't meet that criteria, Kaseb said, but they could have liver scarring without symptoms, and nobody would know. Related : Advertisement That's why screening for liver disease needs to begin at the primary care level, where cases can easily go undetected, said Dr. Mary Rinella, a hepatologist at University of Chicago Medicine and the lead author of guidelines for the management of MASLD. She recommended that doctors use a metric called the Fib-4, which uses routine blood test results to estimate the amount of liver scarring, to screen high-risk patients. These include people who have Type 2 diabetes or obesity with at least one other metabolic risk factor, such as high cholesterol. MASLD is reversible with lifestyle changes, including a healthy diet and increased exercise, and weight-loss drugs have recently been shown to be effective at reversing scarring as well. 'If you stop the reason or the impetus for scarring and injury in the liver, then you're going to have less impetus for the development of cancer,' Rinella said. Alcohol compounds the problem Alcohol-related liver disease is also on the rise. In research published this month, Lee and his colleagues showed that the risk of alcohol-related liver disease among heavy drinkers (at least 10 drinks per week for women and 15 for men) in the United States more than doubled between 1999 and 2020, despite similar alcohol use over that period. That suggests that heavy drinkers today may be more sensitive to the effects of alcohol on the liver than those in the past, Lee said. This may be because the population of heavy drinkers is changing. The researchers found that women, who are more prone than men to develop fat and damage in the liver from alcohol, now make up a greater share of heavy drinkers than they did 20 years ago. So do people with metabolic syndrome, a cluster of metabolic disorders that together raise the risk of diabetes, heart disease and stroke — and compound the damage done by alcohol to the liver. Related : Advertisement Drinking heavily and having a metabolic condition such as obesity can independently damage the liver, but patients who fall in both categories are at an especially high risk. These trends are likely to continue. 'Alcohol use is increasing,' Rinella said. 'Obesity and diabetes are increasing.' 'I expect that we're going to continue to see a high burden of liver disease,' she added. This article originally appeared in .
UPI
a day ago
- Health
- UPI
Most liver cancers are preventable, study says
July 29 (UPI) -- Liver cancer: In most cases, it doesn't have to happen, a new global study finds. Research suggests that 60% of cases of this often deadly disease are preventable by avoiding or treating big risk factors. Those risk factors include viral hepatitis infection, alcohol misuse or a dangerous, obesity-linked buildup of fat in the liver. The finding highlights "a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives," said study first author Dr. Stephen Chan of the Chinese University of Hong Kong. His team issued its findings Monday in a special report on liver cancer published by The Lancet. As Chan's team notes, liver malignancies rank as the sixth most common cancer worldwide and the third-leading cause of cancer deaths. Some countries are being hit much harder than others: China, in particular, is burdened with more than 40% of the world's liver cancer cases, largely due to widespread hepatitis B illness. Without further intervention, cases of liver cancer are expected to nearly double globally by 2050 to more than 1.5 million cases annually, the report found. When cancer affects the body's blood-cleansing organ, it can be very difficult to treat. "It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5% to 30%," noted report co-author Dr. Jian Zhou of Fudan University in China. "We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend." Many cases of liver cancer can be avoided. One preventable cause is metabolic dysfunction-associated steatotic liver disease, or MASLD -- a slow, steady buildup of fat within the liver, often tied to obesity. Up to a third of people worldwide have some level of MASLD, according to the researchers, and as obesity rates rise, cases of the condition are expected to follow suit. By 2040, it is projected that 55% of Americans will have MASLD, upping their odds for liver cancer, the report's authors said. "Liver cancer was once thought to occur mainly in patients with viral hepatitis or alcohol-related liver disease," noted report co-author Dr. Hashem El-Serag of Baylor College of Medicine in Houston. "However, today rising rates of obesity are an increasing risk factor for liver cancer, primarily due to the increase in cases of excess fat around the liver." On the other hand, inroads made against viral hepatitis B (HBV) and C (HCV) mean their impact on liver cancer rates are waning. The authors note in a journal news release that "the proportion of liver cancer cases linked to HBV is expected to decrease from 39% in 2022 to 37% in 2050, while HCV-related cases are projected to drop from 29% to 26% over the same period." Better efforts to vaccinate against hepatitis B and screen for (and treat) hepatitis C could drive down liver cancer rates even further, the team said. Diagnosing and treating MASLD would also help. "One approach to identify patients at high risk of liver cancer would be to introduce screening for liver damage into routine healthcare practice for patients at high risk of MASLD, such as individuals living with obesity, diabetes and cardiovascular disease," El-Serag said in the news release. Better advocacy around healthy diets and regular exercise can also help, he added. Even cutting liver cancer cases by 2% to 5% per year could mean that 9 million to 17 million new cases of liver cancer could be prevented worldwide by 2050. That translates to up to 15 million lives saved, the report's authors said. More information Find out more about MASLD and liver cancer at the Fatty Liver Alliance. Copyright © 2025 HealthDay. All rights reserved.
